AcquisitionsApr 29, 2026, 06:13 AM
BIIB to Acquire Apellis; Q1 Revenue $2.5B, EPS $2.15
AI Summary
Biogen Inc. reported strong first quarter 2026 results and announced a proposed acquisition of Apellis Pharmaceuticals, expected to bolster growth and be accretive in 2027. The company achieved $2.5 billion in total revenue, a 2% increase year-over-year, with GAAP diluted EPS rising 31% to $2.15 and Non-GAAP diluted EPS up 18% to $3.57. Growth products like LEQEMBI and SKYCLARYS showed significant sales increases, and Biogen updated its full year 2026 Non-GAAP diluted EPS guidance to $14.25-$15.25, excluding the Apellis transaction.
Key Highlights
- Proposed acquisition of Apellis Pharmaceuticals, expected to be accretive in 2027.
- Q1 2026 total revenue $2.5 billion, increased 2% year-over-year.
- Q1 2026 GAAP diluted EPS $2.15, increased 31% year-over-year.
- Q1 2026 Non-GAAP diluted EPS $3.57, increased 18% year-over-year.
- LEQEMBI global in-market sales $168 million, up 74% year-over-year.
- SKYCLARYS global revenue $151 million, up 22% year-over-year.
- Full year 2026 Non-GAAP diluted EPS guidance updated to $14.25-$15.25 (excluding Apellis).
- SPINRAZA High Dose Regimen approved in the U.S. by the FDA.